Faculty

Stephen L Graziano, MD

Stephen L Graziano, MD
Appointed 12/10/07
Women's Health Network
2272 Regional Oncology Center
750 East Adams Street
Syracuse, NY 13210
315 464-4353

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Medicine: Hematology and Oncology
  • Upstate Cancer Center: Medical Oncology

Research Programs and Affiliations

  • Cancer Research Institute
  • Medicine

Clinic/Unit

Education & Fellowships

  • Fellowship: University Hospital, SUNY Health Science Center at Syracuse, 1985
  • Residency: University Hospital, SUNY Health Science Center at Syracuse, 1982
  • Internship: University Hospital, SUNY Health Science Center at Syracuse, 1980
  • MD: University of Minnesota Medical School, 1979

Clinical Interests

  • Prognostic Factors in Patients with Non-Small Cell Lung Cancer; lung cancer clinical trials; participation in Cancer and Leukemia Group B studies.

Research Interests

  • Participation in Cancer and Leukemia Group B with  J. Bogart, L. Kohman, S. Lemke, J. Wright, B. Poiesz, K. Zamkoff, S. Grethlein and T. Coyle.

Clinical Trials

  • AACRU RC1126: A Randomized Phase II Trial of Erlotinib Alone or in Combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
    Read more
  • CALGB 30901: Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression After First-line Chemotherapy
    Read more
  • ECOG E5508-Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.
    Read more
  • GSK Protocol BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
    Read more
  • RTOG 1306 - A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
    Read more

Specialties & Certification

  • Internal Medicine
  • Oncology
  • Hematology

Diseases & Conditions Treated

  • All Cancers and Hematological Conditions
  • Lung Cancer
  • Mesothelioma

Treats

  • Adults

Treatments/Services

  • Apheresis
  • Blood Transfusion
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Marrow Transplantation (BMT)
  • Chemotherapy
  • Clinical Trials
  • Conscious Sedation
  • Infusional Therapies
  • Lumbar Puncture
  • Paracentesis
  • Stem Cell Collection Procedures
  • Stem Cell Transplantation
  • Thoracentesis

Current Hospital Privileges

  • Upstate University Hospital

Publications

Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

The Cancer and Leukemia Group B (CALGB) is an NCI sponsored national cooperative group whose goal is to conduct clinical trials of new treatments for neoplastic diseases and related science questions. Protocols are developed with intensive peer review and conducted at over 400 hospitals nationwide, in Canada, and in Europe. The SUNY-Health Science Center Network including the Syracuse VA Medical Center is consistently among the top main member institutions in terms of overall accrual of patients to CALGB studies. CALGB conducts phase I, II, and III multimodality treatment trials, as well as innovative correlative science studies. Current trials test new therapies for cancer of the breast, lung, colon/rectum, bladder, prostate, lymphoma, and leukemias.

Prognostic Factors in Patients with Non-small Cell Lung Cancer. With B. Poiesz, A. Tatum, N. Newman and L. Kohman.

Lung cancer is the leading cause of cancer-related mortality in both men and women in the United States. Seventy-five to eighty percent of cases are of non-small cell lung cancer (NSCLC) histology (adenocarcinoma, squamous cell and large cell anaplastic carcinoma). The well established negative prognostic factors for patients with NSCLC include higher stage, weight loss, poor performance status and the presence of systemic symptoms. During the past several years, our laboratory has investigated the potential prognostic significance of a number of pathological and biological variables in a large group (n=260) of patients with surgically resected stage I (n=193) and II (n=67) NSCLC. Multivariate analysis of this retrospectively studied group of patients has yielded a small number of independent prognostic factors. The following predicted for overall survival and disease free-survival: N-stage, T-stage, antigen A, age, mucin and Ki-67.

We hypothesize that there are important clinical, pathologic, and biological factors that predict for patient outcome and that such factors will be clinically useful for identifying patients that could benefit from additional therapy.

Selected References

Mehdi S.A., Tatum, A.H., Newman, N.B., Gamble, G.P. Etzell, J.E., Weidner, N., Kern, J.A., Sorscher, S.M., Kohman, L.J., and Graziano, S.L. Prognostic markers in resected stage I and II non-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clinical Lung Cancer, 1:59-67, 1999.

Lilenbaum, R.C., Herndon, J.E., List M.A., Desch, D., Watson, D.M., Miller, A.A., Graziano, S.L., Perry, M.C., Saville, W., Chahiniam, P., Weeks, J.C., Holland, J.C., and Green, M.R.  Single-agent versus combination chemotherapy in advanced non-small -cell lung cancer:  The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005.

Graziano, S.L., Herndon, II, J.E., Socinski, M.A., Wang, X., Watson, D., Vokes, E., and Green, M.R.  Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer:  Cancer and Leukemia Group B Study 39901.  Journal of Thoracic Oncology, 3:158-162, 2008.

Clinical Profile Shortcut: http://www.upstate.edu/findadoc/grazians
Faculty Profile Shortcut: http://www.upstate.edu/faculty/grazians